Roy S. Herbst, MD, PhD
机构: Yale School of Medicine | Yale Cancer Center | Smilow Cancer Hospital at Yale-New Haven
每年引用次数
引用次数
引用: 105,712
H-指数: 146
I10-指数 : 487
出版物: 998
TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer
Roy S. Herbst , Diane Prager , Robert Hermann , Lou Fehrenbacher
Journal of Clinical Oncology 23 ( 25) 5892 -5899
1,813
2005
Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials
Ross A. Okimoto , Brian W. Brannigan , Dennis C. Sgroi , Beth Muir
Journal of Clinical Oncology 23 ( 31) 8081 -8092
732
2005
Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib
David A. Eberhard , Bruce E. Johnson , Lukas C. Amler , Audrey D. Goddard
Journal of Clinical Oncology 23 ( 25) 5900 -5909
1,306
2005
A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753).
Saiama N. Waqar , Mary W. Redman , Susanne M. Arnold , Fred R. Hirsch
Clinical Lung Cancer
28
2020
SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study)
Hossein Borghaei , Mary W. Redman , Karen Kelly , Saima N. Waqar
Clinical Lung Cancer
2020
Challenges and approaches to implementing master/basket trials in oncology.
Amy Burd , Richard L. Schilsky , John C. Byrd , Ross L. Levine
Blood Advances 3 ( 14) 2237 -2243
7
2019
Phase II Selection Design Trial of Concurrent Chemotherapy and Cetuximab Versus Chemotherapy Followed by Cetuximab in Advanced-Stage Non–Small-Cell Lung Cancer: Southwest Oncology Group Study S0342
Roy S. Herbst , Karen Kelly , Kari Chansky , Philip C. Mack
Journal of Clinical Oncology 28 ( 31) 4747 -4754
57
2010
Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo
Jieru Meng , Bingbing Dai , Bingliang Fang , B. Nebiyou Bekele
PLoS ONE 5 ( 11) e14124
121
2010
A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer.
Edward S. Kim , Ann M. Mauer , William N. William , Hai T. Tran
Cancer 115 ( 8) 1713 -1722
29
2009
Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer.
Ralph G. Zinner , Frank V. Fossella , Gregory W. Gladish , Bonnie S. Glisson
Cancer 104 ( 11) 2449 -2456
163
2005
Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum‐based therapies
Jan. B. Vermorken , Roy S. Herbst , Xavier Leon , Nadia Amellal
Cancer 112 ( 12) 2710 -2719
140
2008
Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab.
Sarah B. Goldberg , Scott N. Gettinger , Amit Mahajan , Roy S. Herbst
Journal of Clinical Oncology 36 2009 -2009
25
2018
First comprehensive report of impact of genomic alterations, chemotherapy, targeted therapy and immunotherapy on outcomes in the genomics driven squamous master protocol LungMAP.
Vassiliki Papadimitrakopoulou , Mary Weber Redman , David R. Gandara , Fred R. Hirsch
Journal of Clinical Oncology 36 ( 15_suppl) 9019 -9019
1
2018
Prevalence and prognosis of DNA repair deficiency in squamous cell carcinoma (SCC) patients enrolled on the S1400 LungMAP study.
Taofeek Kunle Owonikoko , Mary Weber Redman , Lauren Averett Byers , Katie Griffin
Journal of Clinical Oncology 36 ( 15_suppl) 9055 -9055
2018
Final results of a phase I prospective trial evaluating the combination of stereotactic body radiotherapy (SBRT) with concurrent pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC) or melanoma.
Allison M. Campbell , Roy S. Herbst , Scott N. Gettinger , Sarah B. Goldberg
Journal of Clinical Oncology 36 ( 15_suppl) 9099 -9099
2
2018
Defining and Understanding Adaptive Resistance in Cancer Immunotherapy
Tae Kon Kim , Roy S. Herbst , Lieping Chen
Trends in Immunology 39 ( 8) 624 -631
142
2018
Clinical significance of programmed death ligand-1 expression in non-small cell lung cancer (NSCLC).
Vamsidhar Velcheti , Kurt Schalper , Daniel Carvajal , Lieping Chen
Journal of Clinical Oncology 31 ( 15_suppl) 11075 -11075
1
2013
Addressing tobacco use and cessation in cancer patients: Practices, perceptions, and barriers reported by oncology providers.
Graham Walter Warren , James Roger Marshall , K. Michael Cummings , Benjamin A Toll
Journal of Clinical Oncology 31 1561 -1561
2
2013
A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.
Roy S. Herbst , Michael S. Gordon , Gregg Daniel Fine , Jeffrey Alan Sosman
Journal of Clinical Oncology 31 3000 -3000
270
2013
Multitargeted Tyrosine Kinase Inhibitors in Unselected Patients With Advanced Non–Small-Cell Lung Cancer (NSCLC): Impressions From MONET (the Motesanib NSCLC Efficacy and Tolerability Study)
Daniel Morgensztern , Roy S. Herbst
Journal of Clinical Oncology 30 ( 23) 2805 -2808
3
2012